The US FDA has approved scPharmaceuticals’ sNDA for Furoscix, expanding its indication to include oedema treatment in individuals with CKD.
The US FDA has approved scPharmaceuticals’ sNDA for Furoscix, expanding its indication to include oedema treatment in individuals with CKD.